Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Insulin Articles

Type 1 Glucose Production Pill on the Horizon
What are your thoughts on insulin pumps?
Community’s Positive Effect on Diabetes Management
At the Crossroads, I Choose Insulin
Reduced Insulin May Prevent Exercise-Related Hypoglycemia
An Interview With My Husband, Rick
Living With Type 1 Diabetes
Smaller, Lighter OmniPod Earns FDA Approval
We’re Not Bad, We’re Human
The Penalty of Not Being Able to Afford Care Is Too Expensive
Diabetes Health Reference Charts
Syringes Reference Guide (PDF)
Insulin Pen Needles Reference Guide (PDF)
Insulin Reference Guide (PDF)
Insulin Pumps Reference Guide (PDF)
Infusion Sets Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
Mail Order Reference Guide (PDF)
Mail Order Reference Guide (PDF)
See All Charts…
Insulin Archives
Browse the Insulin Archives
Subscribe to the Medications RSS Feed
Print | Email | Share | Comments (0)

Islet transplant business moves forward with new financing and talent

May 1, 1995

The Neocrin Company is presently one of the leading biomedical companies involved in the research and development of a bio-artificial pancreas. This minimally invasive implantable device will be used for the treatment of insulin dependent diabetes.

Recently, Neocrin announced that it has raised $12.5 million in a self-managed private offering. The company sold approximately 2.5 million shares of stock to both existing and new investors.

In conjunction with the financing, Neocrin also announced that Dr. David W. Sharp, a world renowned islet transplant surgeon, has joined the company as executive vice president of research and medical affairs. While at Washington University, Sharp completed numerous successful human islet transplants.

"Without question, islet transplantation can be expected to demonstrate a dramatic improvement over conventional insulin therapy in helping prevent long-term complications of the disease," claimed Sharp.

Categories: Diabetes, Insulin, Islet & Pancreas Transplant

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - May 1, 1995

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.